Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 29.16
NLNK's Cash to Debt is ranked higher than
71% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. NLNK: 29.16 )
NLNK' s 10-Year Cash to Debt Range
Min: 0.79   Max: N/A
Current: 29.16

Equity to Asset 0.90
NLNK's Equity to Asset is ranked higher than
91% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NLNK: 0.90 )
NLNK' s 10-Year Equity to Asset Range
Min: -5.11   Max: 0.9
Current: 0.9

-5.11
0.9
Interest Coverage 4522.04
NLNK's Interest Coverage is ranked higher than
55% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NLNK: 4522.04 )
NLNK' s 10-Year Interest Coverage Range
Min: 4522.04   Max: 4522.04
Current: 4522.04

F-Score: 4
Z-Score: 31.00
WACC vs ROIC
6.24%
1359.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 66.08
NLNK's Operating margin (%) is ranked higher than
99% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. NLNK: 66.08 )
NLNK' s 10-Year Operating margin (%) Range
Min: -2849.13   Max: 68.12
Current: 66.08

-2849.13
68.12
Net-margin (%) 58.30
NLNK's Net-margin (%) is ranked higher than
98% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NLNK: 58.30 )
NLNK' s 10-Year Net-margin (%) Range
Min: -2852.7   Max: 59.6
Current: 58.3

-2852.7
59.6
ROE (%) 93.48
NLNK's ROE (%) is ranked higher than
99% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. NLNK: 93.48 )
NLNK' s 10-Year ROE (%) Range
Min: -85.27   Max: 78.49
Current: 93.48

-85.27
78.49
ROA (%) 81.16
NLNK's ROA (%) is ranked higher than
100% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. NLNK: 81.16 )
NLNK' s 10-Year ROA (%) Range
Min: -75.86   Max: 66.66
Current: 81.16

-75.86
66.66
ROC (Joel Greenblatt) (%) 847.77
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NLNK: 847.77 )
NLNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -709.08   Max: 799.38
Current: 847.77

-709.08
799.38
Revenue Growth (3Y)(%) 161.80
NLNK's Revenue Growth (3Y)(%) is ranked higher than
99% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NLNK: 161.80 )
NLNK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 161.8
Current: 161.8

0
161.8
» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NLNK Guru Trades in Q2 2014

First Eagle Investment 1,306,970 sh (+12.49%)
First Eagle Investment 7,147 sh (unchged)
» More
Q3 2014

NLNK Guru Trades in Q3 2014

Stanley Druckenmiller 182,500 sh (New)
First Eagle Investment 11,760 sh (unchged)
First Eagle Investment 1,257,619 sh (-3.78%)
» More
Q4 2014

NLNK Guru Trades in Q4 2014

First Eagle Investment 1,406,386 sh (+11.83%)
First Eagle Investment 1,406,386 sh (+11.83%)
First Eagle Investment 12,375 sh (unchged)
Stanley Druckenmiller Sold Out
» More
Q1 2015

NLNK Guru Trades in Q1 2015

Joel Greenblatt 838,221 sh (New)
Paul Tudor Jones 5,380 sh (New)
First Eagle Investment 1,430,700 sh (+1.73%)
First Eagle Investment 10,959 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.30
NLNK's P/E(ttm) is ranked higher than
98% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 14.30 )
NLNK' s 10-Year P/E(ttm) Range
Min: 13.51   Max: 19.34
Current: 14.3

13.51
19.34
Forward P/E 15.17
NLNK's Forward P/E is ranked higher than
96% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 15.17 )
N/A
PE(NRI) 14.30
NLNK's PE(NRI) is ranked higher than
99% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 14.30 )
NLNK' s 10-Year PE(NRI) Range
Min: 13.5   Max: 19.31
Current: 14.3

13.5
19.31
P/B 5.20
NLNK's P/B is ranked higher than
71% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. NLNK: 5.20 )
NLNK' s 10-Year P/B Range
Min: 3.6   Max: 21.14
Current: 5.2

3.6
21.14
P/S 7.70
NLNK's P/S is ranked higher than
83% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. NLNK: 7.70 )
NLNK' s 10-Year P/S Range
Min: 7.22   Max: 1162.5
Current: 7.7

7.22
1162.5
PFCF 16.80
NLNK's PFCF is ranked higher than
98% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 16.80 )
NLNK' s 10-Year PFCF Range
Min: 13.65   Max: 22.15
Current: 16.8

13.65
22.15
POCF 16.24
NLNK's POCF is ranked higher than
97% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 16.24 )
NLNK' s 10-Year POCF Range
Min: 13.32   Max: 21.38
Current: 16.24

13.32
21.38
EV-to-EBIT 7.18
NLNK's EV-to-EBIT is ranked higher than
99% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 7.18 )
NLNK' s 10-Year EV-to-EBIT Range
Min: -36.7   Max: 13.5
Current: 7.18

-36.7
13.5
Current Ratio 14.30
NLNK's Current Ratio is ranked higher than
91% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. NLNK: 14.30 )
NLNK' s 10-Year Current Ratio Range
Min: 0.97   Max: 23.49
Current: 14.3

0.97
23.49
Quick Ratio 14.30
NLNK's Quick Ratio is ranked higher than
92% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NLNK: 14.30 )
NLNK' s 10-Year Quick Ratio Range
Min: 0.97   Max: 23.49
Current: 14.3

0.97
23.49
Days Sales Outstanding 44.03
NLNK's Days Sales Outstanding is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. NLNK: 44.03 )
NLNK' s 10-Year Days Sales Outstanding Range
Min: 40.89   Max: 617.06
Current: 44.03

40.89
617.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.66
NLNK's Price/Net Cash is ranked higher than
85% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. NLNK: 6.66 )
NLNK' s 10-Year Price/Net Cash Range
Min: 5.21   Max: 29.76
Current: 6.66

5.21
29.76
Price/Net Current Asset Value 5.34
NLNK's Price/Net Current Asset Value is ranked higher than
85% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. NLNK: 5.34 )
NLNK' s 10-Year Price/Net Current Asset Value Range
Min: 4.66   Max: 21.93
Current: 5.34

4.66
21.93
Price/Tangible Book 5.15
NLNK's Price/Tangible Book is ranked higher than
75% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. NLNK: 5.15 )
NLNK' s 10-Year Price/Tangible Book Range
Min: 3.93   Max: 14.71
Current: 5.15

3.93
14.71
Price/Median PS Value 0.05
NLNK's Price/Median PS Value is ranked higher than
99% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NLNK: 0.05 )
NLNK' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 4.1
Current: 0.05

0.05
4.1
Price/Graham Number 1.49
NLNK's Price/Graham Number is ranked higher than
97% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NLNK: 1.49 )
NLNK' s 10-Year Price/Graham Number Range
Min: 1.62   Max: 1.94
Current: 1.49

1.62
1.94
Earnings Yield (Greenblatt) 13.90
NLNK's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. NLNK: 13.90 )
NLNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.4   Max: 13.1
Current: 13.9

7.4
13.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small-molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator-initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non-patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NEWLINK GENETICS CORP Financials May 20 2015
The 5 Winners and Losers From ASCO Presentations May 14 2015
Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog May 13 2015
NewLink Genetics shares fall on study continuation May 12 2015
NewLink Genetics shares fall on study continuation May 12 2015
Stocks Stumble In Rising Trade; Pall Soars, NewLink Dives May 12 2015
As Ebola disappears, no useful data seen from vaccine trials -WHO May 12 2015
As Ebola disappears, no useful data seen from vaccine trials -WHO May 12 2015
NewLink's Pancreatic Cancer Vaccine on Long Road to Study Failure May 12 2015
Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers May 11 2015
Rackspace shares fall on revenue outlook May 11 2015
After-hours buzz: Rackspace, Gap, Depomed & more May 11 2015
Newlink shares drop as study data analysis plan goes unchanged May 11 2015
NewLink Genetics' IMPRESS Phase 3 Pancreatic Cancer Trial with Algenpantucel-L to Continue Following... May 11 2015
NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly Report May 11 2015
NewLink Genetics' IMPRESS Phase 3 Pancreatic Cancer Trial with Algenpantucel-L to Continue Following... May 11 2015
NewLink Genetics sees call buying May 08 2015
NEWLINK GENETICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 06 2015
NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis May 05 2015
NewLink Genetics Corporation Provides Operational Update and Reports First Quarter 2015 Financial... May 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK